International Lung Cancer Summit shared a post on X:
“Does PD-L1 alone tell the whole story in resectable NSCLC, or are we missing a broader inflammatory signal?
At ILCS 2025, Patrick Forde discussed why histology and stage might be poor predictors of benefit from neoadjuvant chemo-IO. He highlighted data from CheckMate 816 where an investigational 4-gene signature ~PD-L1, CD8A, STAT1, LAG3~ identified patients with high tumor inflammation who derived substantial EFS benefit.
Can PD-L1 on Blood Immune Cells Predict Who Benefits From Durvalumab in ES-SCLC?
